… with Lantus (insulin glargine). Rezvoglar (insulin glargine-aglr … Drugs in the FDA's Center for Drug … to life-saving medications," Sarah … insulin market, promoting competition and increasing access to vital diabetes treatments. As the FDA …

… their diabetes medicine. We also provide free medications to … FDA. In 2021, the FDA approved two biosimilars of Lantus, an insulin glargine: Rezvoglar (insulin … injections of insulin for treatment of diabetes, having a … in the FDA’s Center for Drug Evaluation …

… some people with diabetes who require insulin still encounter barriers … time to discuss alternative treatment options.” The decision was … a competitor’s basal insulin (Lantus), at a 78% lower … who rely on our diabetes medications,” according to the Sanofi …

… Sanofi’s long-acting insulin Lantus, the FDA has signed off on … trial of 597 patients with type 1 and type 2 diabetes … rapid-acting insulin follow-on Fiasp are among the drugs subject … ’s version of the drug, called Rezvoglar (insulin glargine-aglr).

… New Drugs in the FDA's Centre for Drug Evaluation … Sanofi's basal insulin product Lantus (insulin glargine) – Viatris… daily injections of insulin for treatment of diabetes, having a biosimilar … to these life-saving medications," said Sarah Yim …

… reference product).” The FDA has approved 65 biosimilar … of its best-selling insulin product, Lantus (insulin glargine), by 78% … diabetes therapy to Sanofi’s core asset portfolio in General Medicines … profile.  In November, Doctors Without Borders/Médecins …

… 14 February 2025, the FDA approved Sanofi-Aventis US’s … diabetes mellitus. Merilog™/Merilog™ SoloStar are the first rapid-acting insulin … were two long-acting insulin biosimilar products (insulin glargine) approved in … (reference product: Sanofi’s Lantus®).

Although originator insulin glargine (Lantus) continues to be the leading insulin glargine product … 1 Biological medicines account for 35% of Europe’s pharmaceutical spending, with … billion by 2030. Insulin, a life-saving treatment for diabetes, is among the …

… of the SURPASS trials published in Diabetes Care, adults … SURPASS-3 and titrated insulin glargine (Lantus, Sanofi) in SURPASS … MD, MSc, PhD Medical Specialty Institute Department of … consulting for Armana, Bayer Pharmaceuticals, Bayer AG, Boehringer Ingelheim …

… Medicare, and changes to Medicaid rules that tied drug … continuing expenses for diabetics. California is not … pharmacy for Lantus, the brand name insulin glargine, … drug applications that are high-profile or politically sensitive like insulin, pharmaceutical …